Sangamo Therapeutics Inc (SGMO)

13.75
NASDAQ : Health Care
Prev Close 14.30
Day Low/High 13.65 / 14.40
52 Wk Low/High 2.65 / 15.05
Avg Volume 1.38M
Exchange NASDAQ
Shares Outstanding 83.61M
Market Cap 1.20B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

I've cut a few positions and haven't made any notable buys today.

Sangamo Therapeutics Reaches Analyst Target Price

In recent trading, shares of Sangamo Therapeutics Inc have crossed above the average analyst 12-month target price of $12.60, changing hands for $12.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Interesting SGMO Put And Call Options For February 2018

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the February 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 197 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

September 15th Options Now Available For Sangamo Therapeutics (SGMO)

September 15th Options Now Available For Sangamo Therapeutics (SGMO)

Investors in Sangamo Therapeutics Inc saw new options become available today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

Steady Climb Amid Low Volume

Bulls should curb their enthusiasm.

Short Interest Drops 16% For SGMO

Short Interest Drops 16% For SGMO

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,569,691 share decrease in total short interest for Sangamo Therapeutics Inc , to 8,230,673, a decrease of 16.02% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

We're Swimming in a Sea of Green This A.M.

We're Swimming in a Sea of Green This A.M.

There are few standout stocks, but there is broad strength so far today.

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Seattle Genetics, FibroGen and Sangamo were among the biotech stock movers in premarket trading on June 26.

Shark Bites: Move Along, No Volatility to See Here

Shark Bites: Move Along, No Volatility to See Here

Only minor movement in the market.

Biotech Movers: Sangamo, Epizyme, Revance

Biotech Movers: Sangamo, Epizyme, Revance

Sangamo Therapeutics, Epizyme and Revance were among the biotech stock movers in premarket trading on June 21.

Sangamo Therapeutics Stock Sees Short Interest Make 16.5% Move

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 1,311,426 share increase in total short interest for Sangamo Therapeutics Inc , to 9,274,371, an increase of 16.47% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Market Brushes Off Comey for More Interesting News

Market Brushes Off Comey for More Interesting News

Alibaba and Nordstrom are helping the bulls.

Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency

Companies also Announce Phase 1/2 Clinical Trial Evaluating SB-525 in Adults with Severe Hemophilia A is Now Open for Enrollment

Shark Bites: Focus on the 'Little Picture'

Shark Bites: Focus on the 'Little Picture'

Here's what I'm trading today amid the 'flat with a positive tone' action.

Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy

Collaboration combines Pfizer's heritage in Rare Disease, capabilities in gene therapy, and expertise in hemophilia with Sangamo's deep knowledge in genomic therapies

TheStreet Quant Rating: D (Sell)